The investigations are piling up for blood-testing startup Theranos.The company said Monday that it’s under scrutiny from the Securities and Exchange Commission and the U.S. Attorney’s Office for the Northern District of California.Those probes come on top of an ongoing inspection by the Centers for Medicare and Medicaid Services (CMS).Theranos has positioned itself as a provider of cheaper, more efficient alternatives to traditional medical tests. It claimed it could process ...
